论文部分内容阅读
目的研究培美曲塞(PEM)联合顺铂对比吉西他滨(GEM)联合顺铂的一线治疗晚期非小细胞肺癌的有效性和安全性。方法 2006年10月至2008年10月,50例晚期非小细胞肺癌按随机数字表随机分为PEM组和GEM组各25例,PEM组给予PEM500mg/m2,d1;DDP75mg/m2,d1、2、3。GEM组给予GEM1000mg/m2,d1、8,DDP75mg/m2,d1、2、3,均为21d一周期,至少完成2周期化疗后评价两组的有效率、不良反应、疾病进展时间(TTP)和总生存时间(OS)。结果两组患者均可评价疗效,PEM组总有效率为44.0%,GEM组为40.0%,两组间差异无显著性(P>0.100),TTP及OS方面有统计学意义,但毒副反应方面,血液学、消化道生化学毒性,PEM组明显低于GEM组。结论培美曲塞联合顺铂一线治疗晚期非小细胞肺癌有稳定的治疗效果,更低的毒性,更好的耐受性,对非小细胞肺癌中非鳞癌的疗效是否更佳有待进一步研究观察。
Objective To investigate the efficacy and safety of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer with first-line gemcitabine combined with cisplatin. Methods From October 2006 to October 2008, 50 patients with advanced non-small cell lung cancer were randomly divided into PEM group and GEM group according to random number table. 25 cases were treated with PEM, 500 mg / m2 P5, d1, DDP75 mg / m2, d1,2 3. GEM was given GEM1000mg / m2, d1,8, DDP75mg / m2, d1,2,3, were 21d cycle, at least after the completion of two cycles of chemotherapy were evaluated in the two groups of the efficiency, adverse reactions, disease progression time (TTP) and Total survival time (OS). Results The curative effect was evaluated in both groups. The total effective rate was 44.0% in PEM group and 40.0% in GEM group. There was no significant difference between the two groups (P> 0.100), TTP and OS were statistically significant, but toxic side effects Hematology, gastrointestinal biochemical toxicity, PEM group was significantly lower than the GEM group. Conclusion Pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer has a stable therapeutic effect, lower toxicity, better tolerability, non-small cell lung cancer in non-squamous cell carcinoma is better to be further studied Observed.